Dr Fiona Campbell, Consultant Paediatric Diabetologist Leeds Children’s Hospital Leeds, UK Dr Campbell has been a Consultant in Paediatric Diabetes for almost 30 years. Clinically she leads a large diabetes service at Leeds Children’s Hospital, Leeds. England, UK caring for over 580 patients aged 0-20 years. The Leeds diabetes team has a national and international reputation for research and innovative practice especially in the use of diabetes related technologies and integrating their use into routine clinical care. More recently the team have been turning their attention towards the management of Early-Stage Type 1 Diabetes. Dr Campbell is a member of the BSPED Early Stage T1D Steering Group. She also attends the Early stage T1D Special Interest Group. These groups have been set up to look at how best to screen and monitor the early stages of T1D as well as how best to administer immnunotherapies to modulate the progression of the disease She is current Chair of the National Children and Young Peoples (CYP) Diabetes Clinical Network in England, UK. She has held this role for the last 15 years and believes that this has given her a unique perspective of the national picture in the provision of services and standards of care offered to CYP with diabetes nationally. At the RCPCH, she has been a member of the National Paediatric Diabetes Audit Project Board for the last 14 years as well as Chair of the NPDA Dataset and Methodology Group. She was the clinical advisor at the RCPCH, Policy and Standards Division and during this time led the development of the National CYP Diabetes Quality Programme that ran between 2018-2023. This consisted of Peer Review of services and Quality Improvement Training for all members of 173 diabetes teams across England and Wales Internationally, Dr Campbell is a member of the International Society for Paediatric and Adolescent Diabetes (ISPAD), and her Leeds based clinical service is a member of SWEET- a special group of certified, world-wide Centres of Reference. Dr Campbell has completed a second 3-year term of office on the Council of Healthcare Professionals at Diabetes UK to ensure that the interests of children and young people living with diabetes are addressed. She is currently Co-Chair of the Diabetes UK Healthcare Professionals Advisory Group Dr Fiona Campbell Nov 2025
I have worked in Paediatric Psychology for 15 years providing support to children, young people, families and their health teams about emotional adjustment to chronic health conditions, and coping with acute care (admissions, diagnosis, distressing procedures and relapses) along the way. I have a passion for embedding psychologically informed care into Paediatric care so every patient receives emotionally sensitive care that engages them with their biopsychosocial health and their medical team who empower them to live a life they value. I have supported diabetes teams through training in solution focused approaches, psycho-socially informed consultations which validates the patient's emotional distress and steers meaningful conversations. I currently lead a trust wide staff support service which applies the scientific knowledge offered by psychological models about managing distress in Paediatrics to staff delivering the care. Witnessing pain, distress and loss in patients ultimately affects us as professionals, I aim to enable professionals to let down their professional armoury and connect with this to promote self care which enables the flow of compassionate care towards patients.
Colin Dayan trained in medicine at University College, Oxford, and Guy’s and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves’ Disease in the Laboratory of Marc Feldmann. He then spent a year as an endocrine fellow at the Massachussetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford. He was appointed as an anniversary Chair at the University of Birmingham in 2026.
Prof Dayan has a long established interest in translational research in the immunopathology of type 1 diabetes promoting progress to “insulin free T1D”. He has published first-in-man clinical studies on the development of peptide immunotherapy and the use of nanoparticles in T1D as well as pioneering the use of lymph node and injection site sampling to monitor the response to therapy. Since 2015 he has been a leading member of the UKT1D-Research Consortium which has hosted more than 15 clinical trials in early T1D over 30 sites. He is currently leading on novel trial designs including the T1D Plus platform trial in Europe and Australia to rapidly test combinations of therapies. In collaboration with the Critical Path Institute, he led the TOMI consortium of 21 clinical trials to define the relationship between C-peptide preservation and clinical endpoints and build an FDA/EMA approved clinical trial simulation tool. He is now seeking to define novel endpoints in preclinical T1D as part of the EDENT1FI European programme. Prof Dayan is a committed advocate to finding ways to bring beta cell preservation and delaying the need for insulin therapy into routine clinical practice. In this regard he supported the application for regulatory approval of Tzield to the FDA in 2021 and is working with colleagues to introduce immunotherapy and population screening into the UK.
Dr Renuka Dias BMedSci MBBS FRCPCH PhD Birmingham Renuka Dias is a Consultant Paediatric Endocrinologist working at Birmingham Women and Children’s Hospital and is an Honorary Associate Clinical Professor at the University of Birmingham. She is the Clinical Lead for the National Highly Specialised Service for Wolfram Syndrome (Children) in Birmingham. Research: Type 1 Diabetes: Screening and management for early Type 1 Diabetes and health inequalities in Type 1 Diabetes. She is the lead Paediatrician for the ELSA study (www.elsadiabetes.nhs.uk/) and a part of the EDENT1FI consortium (www.edent1fi.eu) Rare Diseases: She is part of the Life Arc Funded Acceleration of Rare Disease Trials consortium (WP1: Facilitating Recruitment and WP4: Accelerating Trial Delivery). www.birmingham.ac.uk/staff/profiles/applied-health/dias-renuka
Kathleen leads the type 1 diabetes research group at the University of Bristol. The team have a long history in studies of the natural history of type 1 diabetes and in developing high performance tests for islet autoantibodies. Currently the team are recruiting to the Type 1 Diabetes Risk in Adults (T1DRA) study.
Maddie Julian is the Co-Founder and Chief Executive Officer of DigiBete, an award-winning, NHS-funded digital self-management platform and app that supports children, young people, and families living with Type 1 diabetes. She co-founded DigiBete after her own young child was diagnosed with Type 1 diabetes, driving her to make high-quality, age-appropriate diabetes education and support widely accessible online. A teacher by profession, Maddie brings over 15 years of experience in commercial arts, education and community-focused work, and has a strong commitment to peer-supported learning in long-term condition care. Under her leadership, DigiBete has grown into a nationally recognised, clinically approved resource used by NHS clinics across the UK.
Fulya is a Paediatrician working in Diabetes and General Paediatrics at Alder Hey Children’s Hospital in Liverpool. She is the National Speciality Advisor for Children and Young Adults (CYA) in the NHS England diabetes programme and prior to this was the clinical lead for the CYA workstream. Fulya has provided clinical leadership across key programme areas including tackling health inequalities with a focus on improving access to treatment technology, transition and young adult care and improving care and outcomes for young people living with type 2 diabetes. She has led on developing and delivering the CYA Diabetes ‘Getting It Right First Time’ programme and the CYA Diabetes Rightcare Toolkit, to support systems to improve diabetes care locally and reduce unwarranted variation.
Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of early surveillance programmes for pre-type 1 diabetes and is also exploring which therapies are best tested in the prevention arena. He has developed an international reputation for exploring whether exercise can be used to modulate the autoimmune process in type 1 diabetes. He is the Chair of the MS Prevention Taskforce for the Multiple Sclerosis Society to explore treatment parallels across other conditions with similarities to type 1 diabetes. Parth leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 100 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He has served on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. He was previous chair of the Academic subcommittee of The Association of British Clinical Diabetologists having led and supported the setting up of its first research grant funding scheme and national Diabetes Update training programme for doctors specialising in diabetes and endocrinology.
Dr Tabitha Randell has been a consultant in paediatric endocrinology and diabetes at Nottingham Children's Hospital for over 20 years. She was chair of the British Society for Paediatric Endocrinology and Diabetes (BSPED) from 2020-2024 and prior to that, was chair of the BSPED Clinical Committee. She was responsible for devising, negotiating and implementing the Paediatric Diabetes Best Practice Tariff, resulting in a standardisation of diabetes care for children and young people across the whole of England, along with a substantial uplift in funding for all centres meeting the BPT standards and significant improvements in paediatric diabetes outcomes. She is currently co-chair of the BSPED Pre-type 1 Diabetes Special Interest Group along with Rachel Besser and leads the HCP education pathway group within the SIG.
Dr Ruben Willemsen is a Consultant in Paediatric Diabetes and Endocrinology and the Clinical Lead for the Paediatric Diabetes Service at the Royal London Children’s Hospital, Barts Health NHS Trust. He graduated in Medicine from the University of Leiden, the Netherlands in 2002. He obtained his PhD in paediatric endocrinology in 2008 (‘Small at Birth’; Cardiovascular and metabolic health of subjects born SGA and/or preterm and effects of growth hormone treatment) at the Erasmus University of Rotterdam, the Netherlands. After completing his general paediatric training in 2013 in the Sophia Children’s Hospital, Rotterdam, he worked as an Academic Clinical Lecturer at Addenbrooke’s Hospital and the University of Cambridge. Alongside completing his training in paediatric endocrinology and diabetes, he conducted a multi-centre study on the use of dried blood spots to measure C-peptide in children and adolescents with a recent diagnosis of type 1 diabetes. This approach to measure and track β-cell function in patients with a recent diagnosis of type 1 diabetes has been incorporated in a big European research collaborative (INNODIA; www.innodia.eu), and in various clinical trials. He has an interest in early type 1 diabetes, is a member of the BSPED SIG, and started a pre-type 1 clinic in 2025.
Neil Wright is a Consultant Paediatrican with a Sub-speciality interest in Endocrinology & Diabetes based at Sheffield Children’s Hospital. He is the clinical lead for the NHS England funded CEW Service (Complications of excess weight) in Sheffield.
He has developed experience of using immunotherapy in practice as part of clinical trials. He has contributed to the BSPED consensus on Teplizumab and inputted to the NICE review.